Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer
For most patients with salivary gland cancer, there are no effective standard systemic therapies. Although clinical trials of biomarker-led drug therapies have delivered significant recent advances, there remains a need to understand the clinical utility of genomic profiling of cancer as a means to...
Main Authors: | Samuel Rack, Laura Feeney, Brindley Hapuarachi, Helen Adderley, Laura Woodhouse, Guy Betts, George J. Burghel, Kevin J. Harrington, Robert Metcalf |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/5/1133 |
Similar Items
-
Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer
by: Sarina K. Mueller, et al.
Published: (2022-01-01) -
Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma
by: Laura Feeney, et al.
Published: (2021-08-01) -
2021 Update on Diagnostic Markers and Translocation in Salivary Gland Tumors
by: Malin Tordis Meyer, et al.
Published: (2021-06-01) -
Editorial: Diagnosis, epidemiology and treatment of salivary gland carcinomas
by: Imperia Nuzzolese, et al.
Published: (2024-02-01) -
Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
by: Ryutaro Onaga, et al.
Published: (2023-06-01)